Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab

Filing Before Pivotal Data Beats Lilly’s Pre-Phase III Submission

Pair of aces with poker chips
Time will tell if Eisai and Biogen are holding a pair of aces with Aduhelm and lecanemab • Source: Alamy

More from Neurological

More from Therapeutic Category